5 Top Biotech Stocks Providing Healthy Returns

Discover some of the most successful names in the pharmaceutical industry

   
5 Top Biotech Stocks Providing Healthy Returns

Once again, I present to you another reason why the health care sector is a boon for investors looking to dedicate a healthy part of their portfolio to it. Taking a look back at my January and December posts, you’ll notice that some of the companies below have remained on my list for quite some time now. To find out why, simply take a look at my  Portfolio Grader tool, which ranks companies by a number of fundamental and quantitative measures. To make things easier, out of the 5,000 companies I watch on a weekly basis with this tool, I’ve listed the five biotech stocks whose fundamental and quantitative measures have impressed me the most.

Here they are, in alphabetical order. Each one of these stocks gets an “A” or “B” according to my research, meaning it is a “strong buy” or “buy.”

Alexion Pharmaceuticals (NASDAQ:ALXN) is involved with products used in hematology, nephrology, neurology, ophthalmology and cancer. In the last year, ALXN stock has posted a significant gain of 76%. ALXN stock gets an “A” for sales growth, an “A” for earnings growth, a “B” for earnings momentum, a “B” for its ability to exceed the consensus earnings estimates on Wall Street and a “B” for return on equity in my Portfolio Grader tool. For more information, view my complete analysis of ALXN stock.

Amgen (NASDAQ:AMGN) is an independent biopharmaceutical company that develops treatments for a variety of grievous illnesses. AMGN is up 29% in the last year, compared to a gain of just about 6% for the Dow Jones in the same time. AMGN stock gets an “A” for the magnitude in which earnings projections have increased over the past month, an “A” for cash flow and an “A” for return on equity in my Portfolio Grader tool. For more information, view my complete analysis of AMGN stock.

Celgene (NASDAQ:CELG) is involved with treatments for cancer and immune-inflammatory related diseases. In the last 12 months, CELG stock has jumped 40%. CELG stock gets an “A” for sales growth, a “B” for earnings growth, a “B” for earnings momentum, an “A” for the magnitude in which earnings projections have increased over the past month, a “B” for cash flow and an “A” for return on equity in my Portfolio Grader tool. For more information, view my complete analysis of CELG stock.

Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company that is up 15% since last February. GILD stock gets a “B” for earnings momentum, an “A” for cash flow and an “A” for return on equity in my Portfolio Grader tool. For more information, view my complete analysis of GILD stock.

Regeneron Pharmaceuticals (NASDAQ:REGN) is involved with the discovery, development and commercialization of pharmaceutical products. REGN is the biggest winner on this list, up 168% in the past year. REGN stock gets an “A” for the magnitude in which earnings projections have increased over the past month in my Portfolio Grader tool. For more information, view my complete analysis of REGN stock.

Get more analysis of these picks and other publicly traded stocks with Louis Navellier’s Portfolio Grader tool, a 100% free stock rating tool that measures both quantitative buying pressure and eight fundamental factors.


Article printed from InvestorPlace Media, http://investorplace.com/2012/02/5-top-biotech-stocks-providing-healthy-returns-alxn-amgn-celg-gild-regn/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.